(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases...
Stats | |
---|---|
今日成交量 | 28 324.00 |
平均成交量 | 60 430.00 |
市值 | 217.50B |
EPS | €0.881 ( 2023-09-30 ) |
Last Dividend | €0.718 ( 2023-08-10 ) |
Next Dividend | €0 ( N/A ) |
P/E | 37.12 |
ATR14 | €0.120 (0.09%) |
音量 相关性
AstraZeneca PLC 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
AstraZeneca PLC 相关性 - 货币/商品
AstraZeneca PLC 财务报表
Annual | 2023 |
营收: | €45.81B |
毛利润: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2023 |
营收: | €45.81B |
毛利润: | €37.54B (81.95 %) |
EPS: | €3.84 |
FY | 2022 |
营收: | €44.35B |
毛利润: | €31.96B (72.06 %) |
EPS: | €2.12 |
FY | 2021 |
营收: | €37.42B |
毛利润: | €24.98B (66.76 %) |
EPS: | €0.0800 |
Financial Reports:
No articles found.
AstraZeneca PLC Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.764 (N/A) |
€0 (N/A) |
€1.628 (N/A) |
€0 (N/A) |
€0.718 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.540 | 2004-02-18 |
Last Dividend | €0.718 | 2023-08-10 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 40 | -- |
Total Paid Out | €40.56 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.91 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.67 | |
Div. Directional Score | 8.37 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
COP.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
KSC.DE | Ex Dividend Junior | 2023-05-11 | Annually | 0 | 0.00% | |
1U1.DE | Ex Dividend Junior | 2023-05-17 | Annually | 0 | 0.00% | |
TTR1.DE | Ex Dividend Junior | 2023-05-15 | Annually | 0 | 0.00% | |
EBK.DE | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% | |
NCB.DE | Ex Dividend Knight | 2023-08-31 | Quarterly | 0 | 0.00% | |
ADS.DE | Ex Dividend Junior | 2023-05-12 | Annually | 0 | 0.00% | |
XONA.DE | Ex Dividend Knight | 2023-08-15 | Quarterly | 0 | 0.00% | |
G24.DE | Ex Dividend Junior | 2023-06-23 | Annually | 0 | 0.00% | |
PFV.DE | Ex Dividend Junior | 2023-05-03 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.130 | 1.500 | 7.40 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0589 | 1.200 | 8.04 | 9.64 | [0 - 0.3] |
returnOnEquityTTM | 0.159 | 1.500 | 9.34 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.752 | -1.000 | 2.48 | -2.48 | [0 - 1] |
currentRatioTTM | 0.820 | 0.800 | -0.898 | -0.719 | [1 - 3] |
quickRatioTTM | 0.467 | 0.800 | -1.958 | -1.566 | [0.8 - 2.5] |
cashRatioTTM | 0.191 | 1.500 | -0.0488 | -0.0732 | [0.2 - 2] |
debtRatioTTM | 0.283 | -1.500 | 5.28 | -7.92 | [0 - 0.6] |
interestCoverageTTM | 5.13 | 1.000 | 9.21 | 9.21 | [3 - 30] |
operatingCashFlowPerShareTTM | 6.62 | 2.00 | 7.79 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 4.20 | 2.00 | 7.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.731 | -1.500 | 7.08 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.820 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.179 | 1.000 | 8.42 | 8.42 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.361 | 1.000 | 9.10 | 9.10 | [0.2 - 2] |
assetTurnoverTTM | 0.453 | 0.800 | -0.313 | -0.250 | [0.5 - 2] |
Total Score | 10.08 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 39.38 | 1.000 | 6.12 | 0 | [1 - 100] |
returnOnEquityTTM | 0.159 | 2.50 | 9.58 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 4.20 | 2.00 | 8.60 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.518 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 6.62 | 2.00 | 7.79 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.752 | 1.500 | 2.48 | -2.48 | [0 - 1] |
pegRatioTTM | 2.99 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.226 | 1.000 | 6.85 | 0 | [0.1 - 0.5] |
Total Score | 6.67 |
AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。